Angel Guerrero-Zotano
Overview
Explore the profile of Angel Guerrero-Zotano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pena-Enriquez R, Bermejo B, Pollan M, Diaz-Chacon A, Jerez Gilarranz Y, Ponce Lorenzo J, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):12.
PMID: 39922815
Pregnancy-associated breast cancer (PABC), diagnosed during or shortly after pregnancy, is a challenging entity with an aggressive biology and poor prognosis. This study analyzed the clinicopathological characteristics and gene expression...
2.
Lope V, Guerrero-Zotano A, Fernandez de Larrea-Baz N, Antolin S, Benavent Vinuales M, Bermejo B, et al.
J Nutr Health Aging
. 2024 Jul;
28(8):100312.
PMID: 38970849
Objectives: Adherence to healthy lifestyle recommendations has been reported to improve health-related quality of life (HRQL) in breast cancer (BC) patients, but the influence of long-term behavioral changes remains unknown....
3.
Guerrero-Zotano A, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1557-1568.
PMID: 36749874
Purpose: In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to...
4.
Asleh K, Lluch A, Goytain A, Barrios C, Wang X, Torrecillas L, et al.
Clin Cancer Res
. 2022 Nov;
29(2):389-400.
PMID: 36346687
Purpose: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis,...
5.
Lope V, Guerrero-Zotano A, Ruiz-Moreno E, Bermejo B, Antolin S, Montano A, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230628
Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations...
6.
Donat-Vargas C, Guerrero-Zotano A, Lope V, Bermejo B, Casas A, Baena-Canada J, et al.
Eur J Clin Nutr
. 2022 Feb;
76(9):1343-1346.
PMID: 35194197
The Epi-GEICAM study comprises 1017 invasive BC cases matched with controls of similar age (49 ± 9 years) and residence. Diet and OO consumption were collected through a validated food...
7.
Donat-Vargas C, Guerrero-Zotano A, Casas A, Baena-Canada J, Lope V, Antolin S, et al.
Br J Cancer
. 2021 Sep;
125(8):1168-1176.
PMID: 34483338
Background: Whether there are lifetime points of greater sensitivity to the deleterious effects of alcohol intake on the breasts remains inconclusive. Objective: To compare the influence of distinctive trajectories of...
8.
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Nili Gal-Yam E, et al.
Cancer Discov
. 2021 Jun;
11(11):2796-2811.
PMID: 34183353
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and...
9.
Servetto A, Kollipara R, Formisano L, Lin C, Lee K, Sudhan D, et al.
Clin Cancer Res
. 2021 May;
27(15):4379-4396.
PMID: 34011560
Purpose: FGFR1 overexpression has been associated with endocrine resistance in ER breast cancer. We found FGFR1 localized in the nucleus of breast cancer cells in primary tumors resistant to estrogen...
10.
Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Farinas-Madrid L, Rodriguez-Freixinos V, et al.
Sci Rep
. 2021 Feb;
11(1):4433.
PMID: 33627685
The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. Lurbinectedin is an ecteinascidin that generates DNA...